Infectious Clones of RNA Viruses and Vaccines and Diagnostic Assays Derived Thereof

Abstract

An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines.

1 - 20 . (canceled) 
     
     
         21 . A vaccine comprising an infectious clone based on a genome of an RNA virus comprising a PRRS virus, said infectious clone generated by a process comprising:
 a) providing a host cell that is not susceptible to infection by a wild-type of said RNA virus;   b) providing a recombinant nucleic acid based on the genome of said RNA virus wherein said nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or derivative of either; and   c) transfecting said host cell with said recombinant nucleic acid; and   d) selecting for infectious clones.   
     
     
         22 - 24 . (canceled) 
     
     
         25 . The vaccine of  claim 21 , wherein said recombinant nucleic acid comprises at least one nucleic acid sequence encoding a virulence marker and/or a serological marker particular to said wild-type RNA virus, and wherein said at least one nucleic acid sequence has been modified by cloning techniques to effect a change in virulence and/or a change in serological immune response in vivo. 
     
     
         26 . The vaccine of  claim 21  wherein the nucleic acid sequence encoding said virulence and/or serological marker or markers is located within any open reading frames encoding structural viral proteins. 
     
     
         27 . The vaccine of  claim 26  wherein one of said open reading frames is ORF7. 
     
     
         28 . The vaccine of  claim 21  wherein said recombinant nucleic acid comprises at least one open reading frame and wherein said at least one open reading frame is substituted by an ORF7. 
     
     
         29 . The vaccine of  claim 21  wherein said recombinant nucleic acid comprises an insertion of at least one additional heterologous nucleic acid sequence. 
     
     
         30 . The vaccine of  claim 29  wherein said heterologous nucleic acid sequence encodes an antigen. 
     
     
         31 . The vaccine of  claim 21  wherein said recombinant nucleic acid comprises at least one open reading frame and wherein said at least one open reading frame has been modified by cloning techniques to effect a change in virulence and/or a change in serological immune response in vivo.